Satoh S, Suzuki A, Okamura H, Nishimura T
Gan To Kagaku Ryoho. 1982 Jan;9(1):140-5.
A 59-year-old woman with recurrent malignant melanoma of the vulva has well responded to a combination of immunotherapy and chemotherapy. As an immunotherapy, 10KE OK-432 were injected into the tumor twice a week. Chemotherapeutic regimen consisted of intravenous push of 1 mg vincristine on day 1,100 mg dacarbazine from day 1 through 5 and 50 mg nitrosourea (ACNU) on day 5. This treatment was repeated with 4 week intervals. Before treatment, the patient had a 3 X 3 X 5 cm subcutaneous mass on the left vaginal wall near the introitus. Fifty percent objective reduction of the tumor was achieved 6 weeks after commencement of intralegional immunotherapy and chemotherapy, and the tumor almost disappeared 8 months later. At this time, the treatment was changed to a supportive immunotherapy with intramuscular injection of 1KE OK-432 twice a week. But the tumor began to enlarge 2 months later and the patient is now being treated with the same combination therapy. Major side effects were febrile episodes on the day of intratumor injection of OK-432 and nausea, vomiting during the interval of chemotherapy. Anemia was the main hematologic side effect, but leukocytopenia and thrombocytopenia were not severe. The combination of intratumor injection of OK-432 and chemotherapy seems to be effective for the treatment of malignant melanoma.
一名59岁复发性外阴恶性黑色素瘤女性患者对免疫疗法和化疗联合治疗反应良好。作为免疫疗法，每周两次向肿瘤内注射10KE溶链菌制剂OK - 432。化疗方案包括第1天静脉推注1毫克长春新碱、第1天至第5天静脉滴注100毫克达卡巴嗪以及第5天静脉滴注50毫克亚硝基脲（ACNU）。每4周重复一次该治疗。治疗前，患者在阴道口附近的左侧阴道壁有一个3×3×5厘米的皮下肿物。区域内免疫疗法和化疗开始6周后，肿瘤客观缩小了50%，8个月后肿瘤几乎消失。此时，治疗改为每周两次肌肉注射1KE溶链菌制剂OK - 432的支持性免疫疗法。但2个月后肿瘤开始增大，患者现正接受相同的联合治疗。主要副作用为肿瘤内注射OK - 432当天出现发热，化疗间歇期出现恶心、呕吐。贫血是主要的血液学副作用，但白细胞减少和血小板减少并不严重。肿瘤内注射OK - 432与化疗联合似乎对恶性黑色素瘤治疗有效。
